Q&A: A con­ver­sa­tion with GLP-1 co-dis­cov­er­er Jens Ju­ul Holst on the fu­ture of in­cretin-based drugs

Med­i­cines based on glucagon-like pep­tide-1 (GLP-1) have rev­o­lu­tion­ized the treat­ment of di­a­betes and obe­si­ty.

On Sat­ur­day, five sci­en­tists in­volved in the dis­cov­ery and char­ac­ter­i­za­tion of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER